MedPath

The additive effects of Pranlukast in stable asthmatic patients with the regular use of FP/LABA combination drug (2) Open-label, randomized, and cross-over study

Phase 4
Conditions
Asthma
Registration Number
JPRN-UMIN000001007
Lead Sponsor
JA Tohno Kousei Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
50
Inclusion Criteria

Not provided

Exclusion Criteria

1.Past treatments with anti-LT drugs in the previous 3 months. 2.Past treatments with oral corticosteroids in the previous 2 weeks. 3.Chronic obstructive lung disease(COPD) and other respitatory disease. 4.Severe liver, kidney, heart , hematic and other diseases 5.Inappropriate patients from the doctor's viewpoint.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath